Sanofi-Aventis:Sanofi Pasteur To Enter Japan With Pediatric Vaccine

Accès Membre | Client

Lundi 09 nov 2009 | 07:05:38

L'offre EasyBourse

Bourse

Actualités

Analyse

Pédagogie

Easybourse TV

Espaces

SANOFI-AVENTIS

SAN - [ISIN FR0000120578]

Cours : 49,030 € (c)		Variation : --
Marché : Euronext Paris (temps différé)

Acheter

Vendre

Sanofi-Aventis:Sanofi Pasteur To Enter Japan With Pediatric Vaccine

Edited Press Release
PARIS -(Dow Jones)- Sanofi Pasteur, the vaccines division of Sanofi-Aventis (SNY), announced Monday that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine).
Sanofi Pasteur's ActHIB vaccine is marketed in Japan by Daiichi-Sankyo Co., Ltd. (4568.TO), and will be available starting Dec. 19.
The World Health Organization estimates that Hib is responsible for three million serious illnesses and an estimated 400 000 deaths per year worldwide, mainly caused by meningitis and pneumonia. Almost all victims are children under the age of five, those between four and 18 months of age being especially vulnerable. Every year in Japan, about 500 children are affected by this devastating disease, of whom approximately 25 die and 100 suffer from serious sequelae.
Company Web site: www.sanofipasteur.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=IDbR9DERIRN9iLRqXQUEig%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
November 10, 2008 02:21 ET (07:21 GMT)